Monitoring drug residues in donor blood/plasma samples using LC‐(MS)/MS – a pilot study. Issue 5 (21st January 2013)

• Record Type: Journal Article
• Authors: Thevis, Mario; Krug, Oliver; Geyer, Hans; Wenzel, Folker; Bux, Jürgen; Stahl, Linda; Hollmann, Wildor; Thom, Andreas; Schänzer, Wilhelm
• Is Part Of: Drug testing and analysis. Volume 5:Issue 5(2013:May)
• Page Start: 380
• Page End: 383
• Publication Date: 2013-01-21
• Subjects: Drug residues -- mass spectrometry -- blood donation -- fresh‐frozen plasma -- transfusion; Drugs -- Analysis -- Periodicals; Drug testing -- Periodicals; Chemistry, Forensic -- Periodicals; 615.1901
• DOI: 10.1002/dta.1457
• Languages: English
• ISSNs: 1942-7603

Abstract

Abstract : Quality assurance of pharmaceutical products is of particular importance and thoroughly controlled. Among these, the preparation of human plasma follows strict guidelines from the point of donor selection to product processing. While various precautions particularly concerning antiviral treatment as well as quality assessment are standard procedure, tests for drug residues are rarely, if at all, conducted with fresh frozen plasma products. With the constantly increasing sensitivity and specificity of modern analytical instruments, the detection of trace amounts of therapeutics in plasma is feasible and can be applied to blood products where considered appropriate. To estimate the prevalence of a selection of commonly prescribed and over‐the‐counter drugs (including diuretics, beta‐receptor blocking agents, contraceptives, β2 ‐agonists, antibiotics, antidepressants, analgesics, opioids, glucocorticosteroids, benzodiazepines, stimulants, and oral anti‐diabetics) as well as cannabinoids in human donor plasma, a total of 100 specimens (61 female, 39 male) collected at the German Red Cross Organization in 2012 was subjected to an established analytical approach. The methodology was based on protein precipitation followed by liquid chromatographic‐high resolution/high accuracy mass spectrometric analysis. Following initial test results, confirmatory analyses were conducted with respective reference substances employing a conventional liquid chromatography‐triple‐quadrupole mass spectrometer (LC‐MS/MS) apparatus. Out of one hundred samples, five were found to contain diuretics (four hydrochlorothiazide and one torasemide), five contained beta‐receptor blocking agents (four bisoprolol and one metoprolol), one was found with residues of pseudoephedrine (stimulant) and one with drosperinone (contraceptive). Overall, 12% of samples yielded detectable amounts of drug residues at concentrations estimated to levels common to individuals under therapeutic treatment. In addition, six aliquots of different lots of commercially available plasma preparations with solvent‐detergent processing were tested. Here, no drug residues of the targeted therapeutics were detected. Copyright © 2013 John Wiley & Sons, Ltd.